Genetic polymorphisms of long non-coding RNA GAS5 predict platinum-based concurrent chemoradiotherapy response in nasopharyngeal carcinoma patients

摘要: // Zhen Guo 1 , Youhong Wang Yu Zhao 2 Yi Jin Liang An Bin Wu Zhaoqian Liu Xiaoping Chen Honghao Zhou Hui and Wei Zhang Department of Clinical Pharmacology, Xiangya Hospital, Central South University Institute University, Hunan Key Laboratory Pharmacogenetics, Changsha, 410008, P.R. China Translational Radiation Oncology, Province, Cancer Hospital The Affiliated School Medicine, 410013, Correspondence to: Zhang, email: yjsd2003@163.com Wang, wanghui710327@163.com Keywords: nasopharyngeal carcinoma, chemoradiotherapy, toxicity, GAS5, polymorphisms Received: April 11, 2016     Accepted: June 01, 2017     Published: July 31, 2017 ABSTRACT LncRNA GAS5 plays a tumor suppressive role in variety human cancers promises to be novel diagnostic biomarker, therapy target, as well prognostic biomarker. However, the carcinoma (NPC) remains elusive. objective present study was evaluate effect single nucleotide (SNPs) on treatment efficacy toxicity NPC patients receiving chemoradiotherapy. Three potentially functional SNPs were genotyped 267 validated another 238 treated with chemoradiotherapy from southern China. Multivariate logistic regression analyses stratification used estimate association candidate toxic reactions. Our results showed that rs2067079 kept consistent severe myelosuppression neutropenia discovery set (OR=2.403, P=0.009; OR=2.454, P=0.015; respectively), validation (OR=3.653, P=0.027; OR=4.767, P=0.016; combined dataset (OR=1.880, P=0.007; OR=2.079, P=0.005; respectively). CT genotype carriers presented an even more remarkable increased risk (OR=3.878, P=0.003) (OR=3.794, P=0.009) subgroups taking paclitaxel+platinum concurrent regimen. Besides, we found gene-does rs6790, incidence rate decreased 23.56% 17.21% 10% 30.4% 20.9% 17.1% for rs6790 GG vs GA AA carriers. indicate potential lncRNA predictive biomarkers induced reactions patients.